´
113
M. Jukic et al. / Journal of Molecular Structure 979 (2010) 108–114
lone par present on the heteroatom to an antibonding
p
* orbital (n
*), so called ‘‘forbidden” transition is lower in energy than the
p* ‘‘allowed” transition, but the molar absorptivity of the ‘‘for-
of the compound showed bathocromic and hypochromic shifts, as
the solvent polarity increases which results in decreased emission
intensity, and the fluorescence efficiencies are reduced. Reductions
of the fluorescence efficiencies, accompanied by bathochromic
shifts of the emission spectra of compound 2 was depending on
the protonation of the ground state and/or the excited state.
?
?
p
p
bidden” transition is a thousand times smaller than ‘‘allowed” tran-
sition [51]. The effects of halogen substituent which contain
unshared electrons with the electron-withdrawing properties
attached to the aromatic ring change both the intensity as wells
the wavelength of the absorption and emission maximum even
can diminish or destroy fluorescence [52]. This effect can be from
‘‘forbidden” transitions which are related to the effect of the over-
lap of the orbital involved in the electronic excitation.
Because the substituent effects appear to exert a more pro-
nounced effect on emission than on absorption spectra [53], we
examined the fluorescence spectra of compound 2, which have
been measured in six solvents of different polarity and hydrogen
bonding donor ability such as methanol, ethanol, tetrahydrofuran,
N,N-dimethylformamide, 1,2-dichloroethane and heptane. The
concentrations were the same and the measurements were taken
at room temperature. The ultraviolet emission wavelength of the
electronic transitions of the examined compounds are given in
Table 3, and representative spectra are shown in Fig. 5.
Acknowledgements
Support for this study by the Ministry of Science and
Technology of Croatia (Project Nos. 058-0582261-2253 and
119-1193079-3069) is gratefully acknowledged.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
References
[1] G. Jones, in: A.R. Katritzky, C.W. Rees, E.F.V. Scriven (Eds.), Comprehensive
Heterocyclic Chemistry II, vol. 5, Pergamon, Oxford, 1996.
It can be seen from Table 3 that 2-chloro-4-(methoxymethyl)-
6-methyl-5-nitropyridine-3-carbonitrile (2) showed the highest
fluorescence intensity in tetrahydrofuran. The emission spectra
[2] X.D. Yang, Y.Y. Yu, Struct. Chem. 19 (2008) 693.
}
[3] C. Ögretir, N.F. Tay, Í.Í. Özturk, J. Mol. Graph. Model. 26 (2007) 740.
[4] R.N. Castle, S.D. Phillips, in: A.R. Katritzky, C.W. Rees (Eds.), Comprehensive
Heterocyclic Chemistry, vol. 3, Pergamon, Oxford, 1984.
of compounds
2 in DMF is little bathochromically shifted
[5] J.D. Figueroa-Villar, C.L. Carneiro, E.R. Cruz, Heterocycles 34 (1992) 891.
[6] P.S. Dragovich, T.J. Prins, R. Zhou, E.L. Brown, F.C. Maldonado, S.A. Fuhrman, L.S.
Zalman, T. Tuntland, C.A. Lee, A.K. Patick, D.A. Matthews, T.F. Hendrickson, M.B.
Kosa, B. Liu, M.R. Batugo, J.-P.R. Gleeson, S.K. Sakata, L. Chen, M.C. Guzman, J.W.
Meador, R.A. Ferre, S.T. Worland, J. Med. Chem. 45 (2002) 1607.
[7] M.A.A. Bakar, N.D. Hassan, Z. Abdullah, A. Idris, Z. Aiyub, Malay. J. Anal. Sci. 12
(2008) 561.
[8] M.T. Cocco, C. Congiu, V. Onnis, Eur. J. Med. Chem. 35 (2000) 545.
[9] G.G. Danagulyan, L.G. Saakyan, G.A. Panosyan, Chem. Heterocycl. Compd. 37
(2001) 323.
[10] F. Blanco, D.H. O’Donovan, I. Alkorta, J. Elguero, Struct. Chem. 19 (2008) 339.
[11] E.A. Kaigorodova, V.K. Vasilin, E.A. Sidorova, V.E. Zavodnik, G.D. Krapivin,
Chem. Heterocycl. Compd. 40 (2004) 1442.
[12] M.M. Krayushkin, I.P. Sedishev, V.N. Yarovenko, I.V. Zavarzin, S.K. Kotovskaya,
D.N. Kozhevnikov, V.N. Charushin, Russ. J. Org. Chem. 44 (2008) 407.
[13] K.C. Majumdar, S. Mondal, Tetrahedron 65 (2009) 9604.
[14] R.K. Flamm, C. Vojtko, D.T. Chu, Q. Li, J. Beyer, D. Hensey, N. Ramer, J.J. Clement,
S.K. Tanaka, Antimicrob. Agents Chemother. 39 (1995) 964.
[15] S. Nanjunda Swamy, B.G. Sarala, B.S. Priya, S.L. Gaonkar, J. Shashidhara Prasad,
K.S. Rangappa, Bioorg. Med. Chem. Lett. 16 (2006) 999.
(D
kmax = 7 nm) with respect to the emission spectra in EtOH. It
was also observed that the emission spectra of compound 2 in all
aprotic solvents except DMF is hypsochromically shifted with
respect to the spectra in protic solvents such as ethanol or methanol
which is in agreement with literature data that the transitions of
polar bands are affected by solvent polarity. As solvent polarity is
increased
p ?
p* bands undergo red shifts so since excited state
is more polar than the ground state, and hence stabilization is
greater relative to the ground state in polar solvents [51].
Visible emission maxima of the compound 2 (Table 3) showed
bathocromic (
D
kmax = 45 nm) and hypochromic (
D
emax = À1.009 Â
106 dm3 molÀ1 cmÀ1) shifts, as the solvent polarity increases which
results in decreased emission intensity, and the fluorescence effi-
ciencies are reduced.
Furthermore, a minor shoulder emission located at around
450 nm was observed for compound 2 in both, protic and aprotic
solvents, except THF (Fig. 5). This phenomenon may be ascribed
to the twisted intra molecular charge-transfer reactions [53].
Proton donating ability of solvent molecules presumably affects
the solvent dependence of ka,max. It is assumed that the shoulder is
due to protonated or hydrogen-bonded compounds with solvent
molecule at the pyridine nitrogen [54]. The shoulder appears
clearly in the hydrogen bonding donors protic solvents ethanol
and methanol which has the highest proton donating ability while
in the aprotic THF and DMF with no proton donating ability,
respectively, the shoulders are weak [55].
[16] Q. Li, D.T.W. Chu, A. Claiborne, C.S. Cooper, C.M. Lee, K. Raye, K.B. Berst, P.
Donner, W. Wang, L. Hasvold, A. Fung, Z. Ma, M. Tufano, R. Flamm, L.L. Shen, J.
Baranowski, A. Nilius, J. Alder, J. Meulbroek, K. Marsh, D. Crowell, Y. Hui, L. Seif,
L.M. Melcher, R. Henry, S. Spanton, R. Faghih, L.L. Klein, S.K. Tanaka, J.J. Plattner,
J. Med. Chem. 39 (1996) 3070.
[17] L.L. Klein, D.A. DeGoey, S.A. Thomas, C.M. Yeung, C.L. Leone, D.J. Grampovnik,
D.T. Chu, P.A. Lartey, Bioorg. Med. Chem. Lett. 7 (1997) 1167.
[18] (a) W.J. Coates, Eur. Patent 351058, 1997.;
(b) W.J. Coates, Chem. Abstr. 113 (1990) 40711.
[19] (a) P. Raddatz, R. Bergmann, Ger. Patent 360731, 1988.;
(b) P. Raddatz, R. Bergmann, Chem. Abstr. 109 (1988) 54786.
[20] T.B. O’Dell, L.R. Wilson, M.D. Napoli, H.D. White, J.H. Mirsky, J. Pharmacol. Exp.
Ther. 128 (1960) 65.
[21] S.A.S. Ghozlan, A.Z.A. Hassanien, Tetrahedron 58 (2002) 9423.
[22] J.A. Joule, K. Mills, Heterocyclic Chemistry, Chapman & Hall, London, 1995.
[23] H.J. Roth, A. Kleemann, Pharmaceutical Chemistry, Drug Synthesis, vol. 1,
Prentice Hall Europe, London, 1988.
[24] G.D. Henry, Tetrahedron 60 (2004) 6043.
[25] N. Agarwal, P. Srivastava, S.K. Raghuwanshi, D.N. Upadhyay, S. Sinha, P.K.
Shukla, V.J. Ram, Bioorg. Med. Chem. 10 (2002) 869.
4. Conclusions
Compound 2-chloro-4-(methoxymethyl)-6-methyl-5-nitropyri-
dine-3-carbonitrile (2) was synthesized by novel protocol and its
structure was experimentally characterized by means of X-ray Dif-
fraction, IR, NMR and UV–vis spectroscopic spectroscopy tech-
niques. X-ray crystal structure analysis showed that compound 2
crystallizes with two independent molecules in the asymmetric
unit, which are linked separately by two different types of intermo-
lecular interactions. A UV–vis spectrum was recorded in protic and
aprotic solvents. The absorption and the emission were sensitive
towards solvent polarity. The emission spectra of compound 2 ex-
hibit strong solvent polarity dependence. Visible emission maxima
[26] M.Y. Yakovlev, A.V. Kadushkin, N.P. Solov’eva, O.S. Anisimova, V.G. Granik,
Tetrahedron 54 (1998) 5775.
´
´
´
[27] M. Jukic, M. Cetina, G. Pavlovic, V. Rapic, Struct. Chem. 10 (1999) 85.
ˇ
[28] M. Jukic´, A. Hergold-Brundic´, M. Cetina, A. Nagl, J. Vorkapic´-Furac, Struct.
Chem. 14 (2003) 597.
´
´
ˇ
´
[29] M. Jukic, M. Cetina, J. Vorkapic–Furac, A. Golobic, A. Nagl, Acta Crystallogr. C59
(2003) 357.
´
´
[30] M. Cetina, M. Tranfic, I. Sviben, M. Jukic, J. Mol. Struct. 969 (2010) 25.
[31] Oxford Diffraction, Xcalibur CCD System. CrysAlis CCD and CrysAlis RED. Oxford
Diffraction Ltd., Abingdon, England.
[32] G.M. Sheldrick, Acta Crystallogr. A 64 (2008) 112.
[33] A.L. Spek, J. Appl. Crystallogr. 36 (2003) 7.
[34] M. Nasr, J.C. Drach, S.H. Smith, C. Shipman, J.H. Burckhalter, J. Med. Chem. 31
(1988) 1347.